MCLA 128

Drug Profile

MCLA 128

Alternative Names: MCLA-128

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Merus
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 12 Jul 2016 Merus announces intention to submit IND application to the US FDA by the end of 2016
  • 16 Apr 2016 Interim adverse events and pharmacokinetics data from a phase I/II trial in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top